The NLRB was created to protect Americans' rights under the National Labor Relations Act. However, Board vacancies are threatening the NLRB's ability to operate, which has had a real impact on the lives of workers and employers.

So at the kitchen table it's meaningful for millions of retired Americans, particularly those on fixed incomes, and for all of us.

Pay-for-delay settlements are the most egregious form of antitrust violation in my mind.

Thank you very much.

I just want to again thank you for your work.

American consumers and American taxpayers lose out on lower-cost generic drugs to the tune of billions of dollars each year.

this bill that Senator Grassley and I have that has bipartisan support would not affect the vast majority of the drug settlements

Let's be very clear about what these deals are all about.

allows operating companies to exploit the lack of transparency in patent ownership to win a tactical advantage that could not be gained with a direct attack.

We are also a strong supporter of another bipartisan bill, Senate bill 504, the Fair and Immediate Release of Generics Act.

Hatch-Waxman is supposed to be about--at least paragraph 4 certifications--challenging invalid or not infringed patents.

In fact, after the Supreme Court ruling, an industry analyst said in a CNBC interview that the court created a 'holy mess out of this.'

that these particular type of settlements are delaying entry into the market and hurting consumers and the U.S. Government.

To me, when you look at the numbers and the change since those Circuit Court decisions, this is more than just about some patent litigation, this was about a deliberate effort to delay these drugs onto the market to increase profits on the…

I think they assume that because for a number of years they were settled without pay for delay.

We urge Congress to take action on Senate bill 214, the Preserve Access to Affordable Generics Act.

I think that there would be benefits of billions of dollars from outlawing these reverse payment settlements.

The CBO, as we know, expects this legislation would accelerate the availability of generic drugs and save $4.7 billion over 10 years.